Fulcrum therapeutics, inc. reports consolidated unaudited earnings results for the third quarter ended september 30, 2019

Fulcrum therapeutics, inc. reported consolidated unaudited earnings results for the third quarter ended september 30, 2019. for the quarter, loss from operations was $17,006,000 against $9,088,000 reported a year ago. net loss attributable to common stockholders was $17,338,000 against $10,801,000 reported a year ago. net loss per share attributable to common stockholders, basic and diluted was $0.97 against $8.08 reported a year ago.for the nine months, loss from operations was $67,727,000 against $24,247,000 reported a year ago. net loss attributable to common stockholders was $73,682,000 against $27,465,000 reported a year ago. net loss per share attributable to common stockholders, basic and diluted was $10.33 against $23.28 reported a year ago.
FULC Ratings Summary
FULC Quant Ranking